Literature DB >> 29229583

Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Marc Gillard1, Justin Lack2, Andrea Pontier3, Divya Gandla4, David Hatcher5, Adam G Sowalsky4, Jose Rodriguez-Nieves4, Donald Vander Griend5, Gladell Paner6, David VanderWeele7.   

Abstract

BACKGROUND: Ductal adenocarcinoma of the prostate is an aggressive subtype, with high rates of biochemical recurrence and overall poor prognosis. It is frequently found coincident with conventional acinar adenocarcinoma. The genomic features driving evolution to its ductal histology and the biology associated with its poor prognosis remain unknown.
OBJECTIVE: To characterize genomic features distinguishing ductal adenocarcinoma from coincident acinar adenocarcinoma foci from the same patient. DESIGN, SETTING, AND PARTICIPANTS: Ten patients with coincident acinar and ductal prostate cancer underwent prostatectomy. Laser microdissection was used to separately isolate acinar and ductal foci. DNA and RNA were extracted, and used for integrative genomic and transcriptomic analyses. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Single nucleotide mutations, small indels, copy number estimates, and expression profiles were identified. Phylogenetic relationships between coincident foci were determined, and characteristics distinguishing ductal from acinar foci were identified. RESULTS AND LIMITATIONS: Exome sequencing, copy number estimates, and fusion genes demonstrated coincident ductal and acinar adenocarcinoma diverged from a common progenitor, yet they harbored distinct alterations unique to each focus. AR expression and activity were similar in both histologies. Nine of 10 cases had mutually exclusive CTNNB1 hotspot mutations or phosphatase and tensin homolog (PTEN) alterations in the ductal component, and these were absent in the acinar foci. These alterations were associated with changes in expression in WNT- and PI3K-pathway genes.
CONCLUSIONS: Coincident ductal and acinar histologies typically are clonally related and thus arise from the same cell of origin. Ductal foci are enriched for cases with either a CTNNB1 hotspot mutation or a PTEN alteration, and are associated with WNT- or PI3K-pathway activation. These alterations are mutually exclusive and may represent distinct subtypes. PATIENT
SUMMARY: The aggressive subtype ductal adenocarcinoma is closely related to conventional acinar prostate cancer. Ductal foci contain additional alterations, however, leading to frequent activation of two targetable pathways. Published by Elsevier B.V.

Entities:  

Keywords:  CTNNB1 mutations; Coincident foci; Ductal adenocarcinoma; PI3K pathway; PTEN alterations; Predictive biomarkers; Prostate cancer; WNT pathway

Mesh:

Substances:

Year:  2017        PMID: 29229583      PMCID: PMC6614018          DOI: 10.1016/j.euf.2017.12.003

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  38 in total

1.  Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment.

Authors:  Aalok Kumar; Som Dave Mukherjee
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression.

Authors:  D A Brinker; S R Potter; J I Epstein
Journal:  Am J Surg Pathol       Date:  1999-12       Impact factor: 6.394

3.  Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Authors:  Prateek Mendiratta; Elahe Mostaghel; Justin Guinney; Alok K Tewari; Alessandro Porrello; William T Barry; Peter S Nelson; Phillip G Febbo
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

4.  Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.

Authors:  Souzan Sanati; Mark A Watson; Andrea L Salavaggione; Peter A Humphrey
Journal:  Mod Pathol       Date:  2009-07-24       Impact factor: 7.842

5.  TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.

Authors:  Tamara L Lotan; Antoun Toubaji; Roula Albadine; Mathieu Latour; Mehsati Herawi; Alan K Meeker; Angelo M DeMarzo; Elizabeth A Platz; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2009-01-16       Impact factor: 7.842

6.  Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Authors:  Bo Han; Rohit Mehra; Khalid Suleman; Scott A Tomlins; Lei Wang; Nishi Singhal; Katherine A Linetzky; Nallasivam Palanisamy; Ming Zhou; Arul M Chinnaiyan; Rajal B Shah
Journal:  Mod Pathol       Date:  2009-05-22       Impact factor: 7.842

7.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

8.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

9.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization.

Authors:  Jing Chen; Eric E Bardes; Bruce J Aronow; Anil G Jegga
Journal:  Nucleic Acids Res       Date:  2009-05-22       Impact factor: 16.971

10.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors:  Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

View more
  12 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Authors:  Nithesh Ranasinha; Altan Omer; Yiannis Philippou; Eli Harriss; Lucy Davies; Ken Chow; Paolo M Chetta; Andrew Erickson; Timothy Rajakumar; Ian G Mills; Richard J Bryant; Freddie C Hamdy; Declan G Murphy; Massimo Loda; Christopher M Hovens; Niall M Corcoran; Clare Verrill; Alastair D Lamb
Journal:  BJUI Compass       Date:  2021-01-05

Review 3.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

4.  Interactions between Germline and Somatic Mutated Genes in Aggressive Prostate Cancer.

Authors:  Tarun Karthik Kumar Mamidi; Jiande Wu; Chindo Hicks
Journal:  Prostate Cancer       Date:  2019-03-17

Review 5.  Cancer Plasticity: The Role of mRNA Translation.

Authors:  Laura J Lee; David Papadopoli; Michael Jewer; Sonia Del Rincon; Ivan Topisirovic; Mitchell G Lawrence; Lynne-Marie Postovit
Journal:  Trends Cancer       Date:  2020-10-13

6.  Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy.

Authors:  Mengzhu Liu; Kun Jin; Shi Qiu; Pengyong Xu; Mingming Zhang; Wufeng Cai; Xiaonan Zheng; Lu Yang; Qiang Wei
Journal:  Asian J Urol       Date:  2020-05-23

7.  A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.

Authors:  Hiroaki Kobayashi; Takeo Kosaka; Kohei Nakamura; Kazunori Shojo; Hiroshi Hongo; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya
Journal:  BMC Med Genomics       Date:  2021-10-09       Impact factor: 3.063

8.  PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.

Authors:  Harsimar B Kaur; Daniela C Salles; Adina Paulk; Jonathan I Epstein; James R Eshleman; Tamara L Lotan
Journal:  Histopathology       Date:  2020-09-24       Impact factor: 5.087

9.  CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.

Authors:  Qing Zhou; Wei Xiong; Xing Zhou; Rui-Song Gao; Qun-Fang Lin; Hui-Ying Liu; Juan-Ni Li; Xue-Fei Tian
Journal:  Mol Med Rep       Date:  2019-09-19       Impact factor: 2.952

Review 10.  Current Understanding and Management of Intraductal Carcinoma of the Prostate.

Authors:  Bryden Considine; Adebowale Adeniran; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.